LUA005 / Qilu Pharma - LARVOL DELTA

Preclinical development of LUA005: A differentiated bivalent EGFR/cMET bispecific ADC displays strong anti-cancer efficacy and a wider therapeutic window (AACR 2026) - "LUA005 also demonstrated remarkable efficacy in a series of patient-derived xenograft (PDX) models, including those resistant to osimertinib, cetuximab, or immunotherapy. Conclusions LUA005, an EGFR/cMET bispecific ADC with differentiated molecular design, demonstrated superior antitumor efficacy with enhanced therapeutic index. Preclinical studies warranted its further development into clinical trials, which are anticipated to start in early 2026."

ADC • Bispecific • IO biomarker • Preclinical • Oncology • Solid Tumor • EGFR • MET